Characteristics of the 467 HD Patients Receiving High-Dose Chemotherapy and Autologous Stem-Cell Transplantation
| Age at diagnosis (range) Age ≥40 at diagnosis | 27 yr (8-59) 16% |
| Gender (M/F) | 64%/36% |
| Stage I II III IV | 4% 35% 26% 35% |
| B symptoms | 68% |
| Cumulative first-line and salvage treatments Splenectomy Radiotherapy No | 14% 17% |
| Limited field Extended field Chemotherapy ≥3 MOPP <3 MOPP | 38% (including 8% post-ASCT only)45% (including 7% post-ASC T only) 25% 56% |
| Adriamycin containing | 16% |
| Others | 3% |
| Indication for ASCT PSD PRD R1 R2 | 22% 18% 45% 15% |
| Conditioning regimen BEAM CBV TBI + chemotherapy Others | 58% 28% 2% 12% |
| Source of stem cells Bone marrow PBSC | 63% 37% |
| Age at diagnosis (range) Age ≥40 at diagnosis | 27 yr (8-59) 16% |
| Gender (M/F) | 64%/36% |
| Stage I II III IV | 4% 35% 26% 35% |
| B symptoms | 68% |
| Cumulative first-line and salvage treatments Splenectomy Radiotherapy No | 14% 17% |
| Limited field Extended field Chemotherapy ≥3 MOPP <3 MOPP | 38% (including 8% post-ASCT only)45% (including 7% post-ASC T only) 25% 56% |
| Adriamycin containing | 16% |
| Others | 3% |
| Indication for ASCT PSD PRD R1 R2 | 22% 18% 45% 15% |
| Conditioning regimen BEAM CBV TBI + chemotherapy Others | 58% 28% 2% 12% |
| Source of stem cells Bone marrow PBSC | 63% 37% |
Abbreviations: MOPP, mechlorethamine, vincristine, procarbazine, prednisone; ASCT, autologous stem cell transplantation; PSD, primary sensitive disease; PRD, primary refractory disease; R1, first relapse; R2, multiple relapse; BEAM, carmustine, etoposide, cytosine arabinoside, melphalan; CBV, cyclophosphamide, carmustine, etoposide; TBI, total body irradiation; PBSC, peripheral blood stem cell.